Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma
Shirong Li(Army Medical University), Suzanne Lentzsch(UPMC Hillman Cancer Center)
Cited by 18
Related Papers
Multiple myeloma–derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease
|Journal of Clinical Investigation|2016|73
Targeting the Microtubular Network as a New Antimyeloma Strategy
|Molecular Cancer Therapeutics|2011|28
The checkpoint inhibitor PD-1H/VISTA controls osteoclast-mediated multiple myeloma bone disease
|Nature Communications|2023|19
High glucose inhibits ClC-2 chloride channels and attenuates cell migration of rat keratinocytes
|Drug Design Development and Therapy|2015|15